
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of **October 2021**

Commission File Number: **001-40360**

MIND MEDICINE (MINDMED) INC.

(Name of registrant)

**One World Trade Center
Suite 8500
New York, New York 10007**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

" Form 20-F x Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):"

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):"

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MIND MEDICINE (MINDMED) INC.
(Registrant)

Date: October 4, 2021

By: /s/ Robert Barrow

Name: Robert Barrow

Title: Chief Executive Officer

Form 6-K Exhibit Index

**Exhibit
Number**

Document Description

99.1 Material Change Report dated October 4, 2021.

Form 51-102F3

Material Change Report

- Item 1** **Name and Address of Company**
- Mind Medicine (MindMed) Inc. (the “Company”)
1166 Alberni Street, Suite 1604,
Vancouver, British Columbia
V6E 3Z
- Item 2** **Date of Material Change**
- September 29, 2021
- Item 3** **News Release**
- On September 30, 2021, a news release was disseminated through the newswire services of GlobalNewswire and subsequently filed on SEDAR at www.sedar.com.
- Item 4** **Summary of Material Change**
- On September 29, 2021, the Company appointed Andreas Krebs and Carol Vallone as directors of the Company and Bruce Linton ceased to be a director of the Company.
- Item 5** **Full Description of Material Change**
- 5.1** **Full Description of Material Change**
- On September 29, 2021, the Company appointed Andreas Krebs and Carol Vallone as directors of the Company and Bruce Linton ceased to be a director of the Company.
- 5.2** **Disclosure for Restructuring Transactions**
- Not Applicable.
- Item 6** **Reliance on subsection 7.1(2) of National Instrument 51-102**
- Not Applicable.
- Item 7** **Omitted Information**
- Not Applicable.
- Item 8** **Executive Officer**
- For further information, please contact Rob Barrow, Chief Executive Officer of the Company, at 212-220-6633.
- Item 9** **Date of Report**
- October 4, 2021.
-